A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort (HAMA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03755726|
Recruitment Status : Not yet recruiting
First Posted : November 28, 2018
Last Update Posted : November 29, 2018
|Condition or disease|
Malignant hypertension is the most severe form of high blood pressure, fatal if left untreated. It has not disappeared, with an increasing incidence. Patients with the disease, mainly young (35 to 55 years of age), have an unfavorable cardiovascular prognosis (14% of cardiovascular and renal events at 4 years). Despite these facts, scientific research on the subject remains limited. The definitions and diagnostic criteria have not changed since 1929, and the therapeutic recommendations remain empirical.
This first prospective and multicentric registry will increase and modernize the knowledge of the disease. From these data, diagnostic and therapeutic recommendations based on solid scientific evidence could be developed.
The investigators want to first recruit 500 patients and define their prognosis at 5 years. The impact of the patient's phenotype, type and number of target organs affected will be studied.
A modern definition, adapted to these results, could be proposed. The epidemiology of the disease, the care pathways, the target organ disorders and the management carried out in the centers will be described in detail.
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort|
|Estimated Study Start Date :||March 2019|
|Estimated Primary Completion Date :||March 2029|
|Estimated Study Completion Date :||March 2029|
- prognosis [ Time Frame: 5 years ]5-year prognosis for patients with malignant hypertension